Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 8/20 | 0.81 |
| ▸ | PLK1 | P53350 | 5/20 | 0.81 |
| ▸ | CDK4 | P11802 | 6/20 | 0.59 |
| ▸ | CCND1 | P24385 | 4/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.57 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.57 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.57 |
| ▸ | CCND2 | P30279 | 2/20 | 0.52 |
| ▸ | CCND3 | P30281 | 2/20 | 0.52 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619080 | 1.00 | TTK (0.81) | TTKPLK1CDK4CCND1CDK6 | |
| SCHEMBL616945 | 0.90 | TTK (1.00) | TTKPLK1CDK4CCND1CDK6 | |
| SCHEMBL10098801 | 0.82 | TTK (0.83) | TTKPLK1PLK4GAKSTK33 | |
| SCHEMBL10098787 | 0.82 | TTK (0.83) | TTKPLK1PLK4GAKSTK33 | |
| SCHEMBL619365 | 0.82 | TTK (0.83) | TTKPLK1PLK4GAKSTK33 | |
| SCHEMBL617409 | 0.82 | TTK (0.83) | TTKPLK1PLK4GAKSTK33 | |
| SCHEMBL19105978 | 0.82 | TTK (0.74) | TTKPLK1CDK4CCND1CDK6 | |
| SCHEMBL616160 | 0.81 | TTK (1.00) | TTKPLK1CDK4CCND1CDK6 | |
| SCHEMBL619287 | 0.79 | TTK (0.73) | TTKPLK1CDK4CCND1CDK6 | |
| SCHEMBL619501 | 0.77 | MAPK7 (0.83) | TTKPLK1PLK4GAKMAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | TTK 49/4885PLK1 109/4885CDK4 398/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | TTK 41/4885PLK1 110/4885CDK4 355/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | TTK 41/4885PLK1 110/4885CDK4 355/4885 |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | TTK 66/4885PLK1 117/4885CDK4 418/4885 |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | TTK 41/4885PLK1 110/4885CDK4 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.